Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2015-2022

Wildwood Ventures
350+ Pages - WILD10946
$3,495.00

The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies.

This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report covers details of co-promotion and co-marketing agreements from 2015 to 2022.

For pharmaceutical and biotechnology professionals, the report supplies a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all co-promotion and co-marketing deals announced since 2015 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of co-promotion and co-marketing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of each type of deal.

Chapters 3 and 4 provide an overview of the structure of co-promotion and co-marketing deals, respectively. Each chapter includes numerous case studies to enable understanding of both pure co-promotion/marketing deals and multicomponent deals where co-promotion/marketing forms a part.

Chapter 5 provides a review of the leading co-promotion and co-marketing deals since 2015. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 6 provides a review of the top 25 most active biopharma companies in co-promotion and co-marketing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 7 provides a comprehensive and detailed review of co-promotion and co-marketing deals signed and announced since 2015 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing deal making since 2015.

In addition, a comprehensive appendix is provided organized by co-promotion and co-marketing company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing partnering in the research, development and commercialization of technologies and products.

Key benefits

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2020 report provides the reader with the following key benefits:

In-depth understanding of co-promotion and co-marketing deal trends since 2015
Analysis of the structure of co-promotion and co-marketing agreements with numerous real life case studies
Comprehensive access to over 350 actual co-promotion and co-marketing deals entered into by the world’s biopharma companies
Insight into the terms included in a co-promotion and co-marketing agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 report is intended to provide the reader with an in-depth understanding of the co-promotion and co-marketing trends and structure of deals entered into by leading biopharma companies worldwide.

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 includes:

Trends in co-promotion and co-marketing dealmaking in the biopharma industry since 2015
Analysis of co-promotion and co-marketing deal structure
Case studies of real-life co-promotion and co-marketing deals
Access to over 350 co-promotion and co-marketing deal records
Detailed access to actual co-promotion contract documents
The leading co-promotion and co-marketing deals by value since 2015
Most active co-promotion and co-marketing dealmakers since 2015
The leading co-promotion and co-marketing partnering resources


In Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Therapeutic area
Technology area

Each deal title links via Weblink to an online version of deal record as found in the Current Agreements deals and alliances database, providing easy access to each deal record on demand.

The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 report provides comprehensive access to records for over 350 co-promotion and co-marketing deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise co-promotion and co-marketing rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

'

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in co-promotion and co-marketing dealmaking

2.1. Introduction
2.2. Difference between co-promotion and co-marketing deals
2.3. Trends in co-promotion deals since 2015
2.3.1. Co-promotion and co-marketing dealmaking by year, 2015 to 2022
2.3.2. Co-promotion and co-marketing dealmaking by phase of development, 2015 to 2022
2.3.3. Co-promotion and co-marketing dealmaking by industry sector, 2015 to 2022
2.3.4. Co-promotion and co-marketing dealmaking by therapy area, 2015 to 2022
2.3.5. Co-promotion and co-marketing dealmaking by technology type, 2015 to 2022
2.3.6. Co-promotion and co-marketing dealmaking by most active company, 2015 to 2022

2.4. When co-marketing can be useful

2.5. When co-marketing is the only option

2.6. Pure deals and multi-component deals
2.6.1. Attributes of pure co-promotion deals
2.6.2. Attributes of co-promotion in multi-component deals

2.7. Reasons for including co-promotion options in a deal

2.8. Uptake of co-promotion rights

2.9. Co-promotion rights as bargaining chips

2.10. Aligning partners to make the co-promote work

2.11. The future of co-promotion as part of multicomponent deals

Chapter 3 – Overview of co-promotion deal structure

3.1. Introduction

3.2. Pure versus multi-component co-promotion deals

3.3. Pure co-promotion agreement structure
3.3.1. Example co-promotion agreements
3.3.1.a. Case study 1
3.3.1.b. Case study 2

3.4. Co-promotion rights as part of a wider alliance agreement

3.4.1. Example co-promotion option clauses
3.4.1.a. Case study 3
3.4.1.b. Case study 4
3.4.2. Example co-promotion right clauses
3.4.2.a. Case study 5
3.4.2.b. Case study 6

3.5. Embedded co-promotion rights enabling third party engagement

3.5.1. Example co-promotion clauses enabling third party engagement
3.5.1.a. Case study 7

Chapter 4 – Overview of co-marketing deal structure

4.1. Introduction

4.2. Co-marketing agreement structure

4.2.1. Example co-marketing agreements
4.2.1.a. Case study 8
4.3. Co-marketing rights as part of a wider alliance agreement

4.3.1. Example co-marketing right clauses
4.3.1.a. Case study 9

Chapter 5 – Leading co-promotion and co-marketing deals

5.1. Introduction
5.2. Top co-promotion and co-marketing deals by value

Chapter 6 – Top 25 most active co-promotion and co-marketing dealmakers

6.1. Introduction
6.2. Top 25 most active co-promotion and co-marketing dealmakers

Chapter 7 – Co-promotion and co-marketing agreement contracts directory 2015-2022

7.1. Introduction
7.2. Co-promotion and co-marketing deals with contracts 2015 to 2022

Appendices

Appendix 1 – Co-promotion and co-marketing deals by company A-Z
Appendix 2 – Co-promotion and co-marketing deals by stage of development
Appendix 3 – Co-promotion and co-marketing deals by deal type
Appendix 4 – Co-promotion and co-marketing deals by therapy area
Appendix 5 – Co-promotion and co-marketing deals by technology type
Appendix 6 – Deal type definitions

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

TABLE OF FIGURES

Figure 1: Definition of co-promotion and co-marketing
Figure 2: Trends in co-promotion and co-marketing deal announcements, 2015 to 2022
Figure 3: Co-promotion and co-marketing deals signed at each phase of development, 2015 to 2022
Figure 4: Co-promotion and co-marketing deals by industry sector, 2015 to 2022
Figure 5: Co-promotion and co-marketing deals by therapy area, 2015 to 2022
Figure 6: Co-promotion and co-marketing deals by technology type, 2015 to 2022
Figure 7: Top 25 most active co-promotion and co-marketing dealmakers, 2015 to 2022
Figure 8: Situations where co-marketing can prove useful
Figure 9: Key components of a pure co-promotion deal
Figure 10: Key components of a multi-component co-promotion deal
Figure 11: Example deals where co-promotion options have been actively exercised, since 2000
Figure 12: Issues in implementing co-promotion agreements
Figure 13: Co-promotion agreements – what should a contract include?
Figure 14: Components of the co-promotion deal structure
Figure 15: Components of the co-marketing deal structure
Figure 16: Top co-promotion and co-marketing deals by value since 2015
Figure 17: Most active co-promotion and co-marketing dealmakers 2015 to 2022

3D Medicines, 10X Genomics, Abbvie, Abveris, ACADIA Pharmaceuticals, Acceleron Pharma, Accent Therapeutics, Accinov, Accuray, ACEA Biosciences, Acelrx Pharmaceuticals, Acerus, AC Immune, ACIST Medical Systems, Adaptimmune, Adhera Therapeutics, Advaita, Advanced Analytical Technologies, AEterna Zentaris, Affibody, Agena Bioscience, Agenus Bio, Agilent Technologies, Aignostics, AiLife Diagnostics, AirXpanders, Ajinomoto, Akoya Biosciences, Albany Molecular Research, Alector, Alexion Pharmaceuticals, Alfasigma, ALK-Abello, Allcyte, Allegis Pharmaceuticals, Allergan, Almirall, Alphaeon, Alphazyme, Alyvant, Amgen, Amneal Pharmaceuticals, AMRA, AMRA Medical, Andrew Alliance, Apellis Pharmaceuticals, Applied Cells, Applied DNA Sciences, Applied Spectral Imaging, Aratana Therapeutics, ArcherDX, Arcis Biotechnology, Arcturus Therapeutics, Arcus Biosciences, argenx, Argonaut Manufacturing Services, Aries Pharmaceuticals, Arkema, Armune Bioscience, ArQule, Arrowhead Pharmaceuticals, Arvinas, Asahi Kasei, Ascend Therapeutics, Ascentage Pharma, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Aurora Spine, Automated Systems of Tacoma, Avid Bioservices, Axcend, Aytu BioPharma, Aziyo Biologics, Basilea Pharmaceutica, Bausch & Lomb, Baxalta, Bayer, B Braun, BD Biosciences, Beam Therapeutics, BeiGene, Belintra, Berlin Chemie, BGI, BGI Americas, BioAge Labs, Biocrates, Biodextris, Biogen, Biognosys, Biological Industries, BioNano Genomics, BioNTech, BioTek Instruments, Blake Insomnia Therapeutics, Blanchette Rockefeller Neurosciences Institute, Bluebird Bio, Blueprint Medicines, Boehringer Ingelheim, Bolt Biotherapeutics, BOWA Medical, Bracco Imaging, BrainLAB, BridgeBio Pharma, Bristol-Myers Squibb, Brooks Life Science Systems, Bruker, Burning Rock, Cambrooke Therapeutics, Capsida Biotherapeutics, Cardiome Pharma, Carl Zeiss, Catalent, CC Pharma, Celgene, Cellectricon, Cellenion, Cellular Dynamics International, Cellular Research, Centogene, Century Therapeutics, Cevec Pharmaceuticals, Chime Biologics, Chromocell, Cipher Pharmaceuticals, Clarify Medical, Clearbridge Biomedics, CloudHealth Genomics, COBO Technologies, Codexis, CompleWare, Concordia Pharmaceuticals, Consortia Health, Corazon, CRISPR Therapeutics, Crown Bioscience, CSL, CStone Pharmaceuticals, Cue Biopharma, Cumberland Pharmaceuticals, CureVac, Curio Genomics, Cyclica, Cynergi Health Partners, CytomX Therapeutics, CytoSorbents, Daiichi Sankyo, DARA BioSciences, Delic, Denali Therapeutics, DePuy, DexCom, Diabetes Tools, Dicerna Pharmaceuticals, DirectView Security Systems, Domainex, Dova Pharmaceuticals, Dovetail Genomics, Eagle Genomics, Eagle Pharmaceuticals, EA Pharma, EarlySense, Echolight Medical, Eckert & Ziegler, ECMOHO, eFFECTOR Therapeutics, Egalet, Eigen, Eisai, Elanco, Elekta, Element Biosciences, Eli Lilly, Elucidata, EMD Serono, Empatica, Entellus Medical, Enterome Bioscience, EOS Imaging, Epicypher, Epizyme, EPS International, Eton Pharmaceuticals, Everledger, Evosep, eWellness Healthcare, Exact Sciences, Fabric Genomics, Fate Therapeutics, Ferring Pharmaceuticals, Fidelis Research, Fio, FlowJo, Fluidigm, Foghorn Therapeutics, Fortelinea Software Systems, Fresenius Medical Care, Fusion Pharmaceuticals, G1 Therapeutics, Galapagos, GANZIMMUN Diagnostics, GE Healthcare, Genentech, Genetron Health, Genialis, Genmab, Genomoncology, Genoox, Genosity, George Clinical, Gilead Sciences, GlaxoSmithKline, Glenmark Pharmaceuticals, Goldfinch Bio, Great Bay Bio, Greiner Bio-One, GT Research, Guerbet, Guohong Guokang (Beijing) Health Technology Development, H3 Biomedicine, HalioDx, Halyard Health, Hanmi Pharmaceutical, Harbin Pharmaceutical Group, Harbour Antibodies, HarkerBIO, HD Biosciences, HeartGenetics, Heartseed, Helsinn Healthcare, Helsinn Therapeutics, Henkel, Hepregen, Herman Miller-Nemschoff, High Beauty, Hitachi Medical Systems Europe, Hormosan Pharma GmbH, Iagnosis, IBA, Ibex Medical Analytics, IBM Watson Health, Icagen, Iconic Therapeutics, IDbyDNA, Idorsia, Igentify, Illumina, ImaBiotech, Immatics Biotechnologies, Immunicon, ImmunityBio, ImmunoGen, Immunomedics, Incyte, Indegene Lifesystems, Innara Health, Innate Pharma, Innovent Biologics, Inscopix, Insitro, Inspirion Delivery Sciences, Intabio, Integrated DNA Technologies, Intellia Therapeutics, Ionis Pharmaceuticals, IROA Technologies, Ironwood Pharmaceuticals, iTeos Therapeutics, Janssen Biotech, Janssen Pharmaceuticals, Jiangsu Alphamab, Jiangsu Chia Tai Tianqing Pharmaceutical, Jointpoint, Joylux, Jumpcode Genomics, K2M, Kadmon Pharmaceuticals, Kailos Genetics, Kaleo, Kerma Medical Products, Konica Minolta, Kowa Pharmaceuticals America, KSQ Therapeutics, KVP International, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Kyverna Therapeutics, L1 Systems, Leica Biosystems, Leica Microsystems, LEO Pharma, Lexicon Pharmaceuticals, Lexington Medical, LG Life Sciences, Lord Global, Loxo Oncology, Luqa Pharmaceuticals, Luxcel Biosciences, Lygos, Macherey-Nagel, Macrogenics, Mainz Biomed, Malvern Instruments, MannKind Biopharmaceuticals, Mazor Robotics, MedHelp, Medical Enterprises Distribution, Medicines360, Medigus, MedImmune, Medis, Medovate, Medtronic, MEI Pharma, Menarini, Menarini Silicon Biosystems, Merck and Co, Merck KGaA, Mesoblast, Metavant, MGC Diagnostics, MGI Tech, Microsaic Systems, Microsoft, Midatech, Miltenyi Biotec, Mission Bio, Mission Pharmacal, Mitsubishi Chemical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Moderna Therapeutics, Molnlycke Health Care, Momenta Pharmaceuticals, Morphic Therapeutic, MorphoSys, MRM Proteomics, MSD, Multispan, MYOS, Myovant Sciences, Nanion, Nano3D Biosciences, NanoString Technologies, NantKwest, NantPharma, Napo Pharmaceuticals, Ncardia, Nestle Health Science, NeuPath Health, Neurexpert, Neurocrine Biosciences, Neurotrope BioScience, Newomics, New York Center for Nanomedicine Research, Nexa3D, Nexel, Next&Bio, NGM Biopharmaceuticals, Nkarta Therapeutics, Novartis, Novogene, Novo Nordisk, Nrgene, Nucleai, Nurix, nView Medical, ODI Pharma, Olympus Medical Systems, OncoSec Medical, ONK Therapeutics, Ono Pharmaceutical, OpGen, OptiNose, Orapharma, Ortho-Clinical Diagnostics, Orthofix, Osteopore International, Otonomy, Otsuka, Oxford BioMedica, Pacific Biosciences, Pacira Biosciences, Paragon Bioservices, Pfizer, Pharmaceutics International, Phenomenex, PierianDx, Pieris, Piramal, Pivot Pharmaceuticals, PositiveID, Poxel, Precipio Diagnostics, Precision BioSciences, PrecisionLife, Predicine, Pressure BioSciences, Protagonist Therapeutics, Protea Biosciences, Protean BioDiagnostics, Protein Metrics, Proteos, Proteovant Therapeutics, ProTom International, PSI (Population Services International), Purdue Pharma, PureHoney Technologies, Pure Pharmaceuticals, QED Therapeutics, Qiagen, Quanta, Radformation, Rainbow Scientific, RainDance Technologies, Rakuten Medical, RaySearch Laboratories, RedHill Biopharma, Regenxbio, Relay Medical, Relay Therapeutics, Resonant Specific Technologies, Revolution Medicines, Rigel Pharmaceuticals, Roche, Roche Diagnostics, Roivant Sciences, Rosetta Genomics, Royal Philips Electronics, Rubicon Genomics, S2 Genomics, Sage Therapeutics, Sajo Consulting, Salix Pharmaceuticals, Sanofi, Sanofi-Aventis, Santen Pharmaceutical, Sarepta Therapeutics, Sato Pharmaceutical, Schrodinger, Sciex, Scorpion Therapeutics, Seagen, Seattle Genetics, Senshinkai Eye Institute, Seracare Life Sciences, Seren Pharmaceuticals, Seres Therapeutics, Shimadzu, Shionogi, Silicon Biosystems, Simcere Pharmaceuticals, Sirtex Medical, SK Biopharmaceuticals, Solid Biosciences, Sorrento Therapeutics, Sosei, SoTAX, SparingVision, Spectrum Pharmaceuticals, SPI Pharma, SpiroChem, Staar Surgical Co, Stealth BioTherapeutics, Stoke Therapeutics, StrideBio, Stryker, STU, Sumitomo Dainippon Pharma, Suneva Medical, Sunovion Pharmaceuticals, Sun Pharmaceutical, SurGenTec, Swift Biosciences, Swixx Biopharma, Synaptive Medical, Syndax Pharmaceuticals, Taiho, Taisho Pharmaceutical, Takeda Pharmaceutical, Tango Therapeutics, Tecan, Teijin, Telix Pharmaceuticals, Terumo, Terumo Blood and Cell Technologies, Tetraphase Pharmaceuticals, Theravance, Thermo Fisher Scientific, Threshold Pharmaceuticals, Tilak Healthcare, Tilray, Tissue Analytics, Titan Pharmaceuticals, Tolmar, TOMI Environmental Solutions, Tracey Technologies, TRACON Pharmaceuticals, Trovita Health Science, TTP LabTech, Twist Bioscience, Tyme Technologies, UCB, Ultivue, Ultragenyx Pharmaceuticals, Uni-Bio Science, Unisys, Universal Cells, Urovant Sciences, US WorldMeds, Verity Pharmaceuticals, Vertex Pharmaceuticals, Vertice Pharma, Vida Diagnostics, Vifor Pharma, Visiopharm, ViveBio, Vivus, Waters Corporation, WAVE Life Sciences, Wyatt Technology, Xellia Pharmaceuticals, Xencor, Xoran Technologies, ZAI Laboratory, Ziath, Zymeworks

$3,495.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports